Due to ongoing difficulties in managing multiple tumor progressions and demonstration of positive immunohistochemistry for phospho-ERK, based on previous publications compassionate access to the MEK inhibitor, trametinib, was sought as it was thought this may be effective.3,6,7. Here, MAPK1 is linked to neoplasm.